A 28-year-old man with pancytopenia undergoes bone marrow examination. His marrow shows hypocellularity with < 5% blasts and no dysplasia. Cytogenetics are normal. Which single feature best distinguishes acquired aplastic anemia from inherited bone marrow failure syndromes (Fanconi anemia, dyskeratosis congenita) in this patient?

## Distinguishing Acquired from Inherited Aplastic Anemia ### Diagnostic Challenge **Key Point:** Both acquired aplastic anemia and inherited bone marrow failure syndromes (IBMFS) present with **hypocellular marrow and pancytopenia**. The key discriminator is **chromosomal fragility testing** (DEB/MMC), which reveals clastogenic response in inherited syndromes but not in acquired aplastic anemia. ### Comparison Table: Acquired vs Inherited Aplastic Anemia | Feature | Acquired Aplastic Anemia | Inherited IBMFS (Fanconi, DKC) | | --- | --- | --- | | **DEB/MMC test** | Negative (no excess breaks) | Positive (excess chromosomal breaks) | | **Age of onset** | Any age (often 20–40 yrs) | Often childhood/young adult | | **Physical stigmata** | Absent | Present (thumb anomalies, short stature, skin changes) | | **Cytogenetics (baseline)** | Normal | May be normal initially | | **Cancer risk** | Moderate (MDS/AML ~5–10%) | High (MDS/AML ~30–50%) | | **Bone marrow morphology** | Hypocellular, no dysplasia | Hypocellular, no dysplasia | | **Response to IST** | 60–70% response | Poor response | ### Why DEB/MMC Testing is Definitive **High-Yield:** **DEB (diepoxybutane) or MMC (mitomycin C) testing** induces chromosomal breaks in cells from patients with Fanconi anemia and other IBMFS due to defective DNA repair mechanisms. This test is: - **Positive** in inherited syndromes → excess breaks (> 5–10 breaks per cell in Fanconi anemia). - **Negative** in acquired aplastic anemia → normal breakage pattern. **Mnemonic:** **DEB/MMC = DNA Excision Breakage / Mitomycin C** — reveals the underlying DNA repair defect in IBMFS. ### Clinical Pearl **Clinical Pearl:** A young patient with pancytopenia and **no physical stigmata** may still have an inherited syndrome; conversely, an older patient with **acquired aplastic anemia** may have subtle stigmata mimicking IBMFS. DEB/MMC testing bypasses clinical ambiguity and is the **gold standard** for screening all newly diagnosed aplastic anemia patients, especially those < 40 years old. ### Diagnostic Flowchart ```mermaid flowchart TD A[Pancytopenia + Hypocellular Marrow]:::outcome --> B{Age < 40 or family history?}:::decision B -->|Yes or unclear| C[Perform DEB/MMC test]:::action B -->|No| D[Likely acquired aplastic anemia]:::outcome C --> E{Excess chromosomal breaks?}:::decision E -->|Yes| F[Inherited IBMFS<br/>Fanconi/DKC/SDS]:::outcome E -->|No| G[Acquired Aplastic Anemia]:::outcome F --> H[Avoid alkylating agents<br/>High-dose chemotherapy]:::urgent G --> I[Consider IST or HSCT]:::action ``` **Key Point:** DEB/MMC testing is **mandatory** in all newly diagnosed aplastic anemia, particularly in young patients, because inherited syndromes have dramatically different prognosis and treatment implications.